NewAmsterdam Pharma (NAMS) Operating Expenses (2023 - 2026)

NewAmsterdam Pharma has disclosed Operating Expenses across 4 years of filings, most recently posting $61.5 million for Q1 2026.

• Operating Expenses for Q1 2026 came in at $61.5 million, down 14.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $237.7 million (changed 0.37% YoY), and the FY2025 annual result was $248.2 million, up 11.87% from the prior year.
• Operating Expenses came in at $61.5 million for Q1 2026 at NewAmsterdam Pharma, down from $66.0 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $71.9 million in Q1 2025 to a low of $44.2 million in Q2 2023.
• The 4-year median for Operating Expenses is $54.9 million (2024), against an average of $56.0 million.
• Across the five-year window, Operating Expenses gained 26.41% in 2025 and slipped 14.52% in 2026, its largest moves.
• NewAmsterdam Pharma's Operating Expenses stood at $51.9 million in 2023, then grew by 7.95% to $56.0 million in 2024, then grew by 17.88% to $66.0 million in 2025, then slipped by 6.9% to $61.5 million in 2026.
• The last three Operating Expenses figures came in at $61.5 million (Q1 2026), $66.0 million (Q4 2025), and $55.5 million (Q3 2025), per Business Quant data.